Navigation Links
LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Date:9/1/2009

ses," said Roger E. Morgan, M.D., Chief Medical Officer, Kowa Research Institute. "With sustained efficacy, low rates of discontinuation due to adverse events and steady, progressive increases in HDL-C observed over 52 weeks, LIVALO shows great promise for the long-term treatment of patients with hypercholesterolemia or mixed dyslipidemia."

Study 1

A total of 830 patients were randomized to one of four treatment groups: LIVALO (2 mg or 4 mg) or atorvastatin (10 mg or 20 mg), once daily. Results showed that LIVALO was comparable to atorvastatin in terms of reduction in LDL-C, and no significant differences emerged in the other endpoints. Adverse events with LIVALO and atorvastatin were also similar.

Study 2

A total of 857 patients were randomized to LIVALO (2 mg or 4 mg) or simvastatin (20 mg or 40 mg), once daily. Results showed that LIVALO 4 mg and simvastatin 40 mg were comparable in LDLC reduction, with low-dose LIVALO (2 mg) resulting in a greater reduction in LDL-C than simvastatin 20 mg. Additionally, low-dose LIVALO also showed significantly better decreases in total cholesterol and non-HDL-C than simvastatin 20 mg. Moreover, the percentage of patients who met the LDL-C goal, according to EAS guidelines, was also greater with low-dose LIVALO compared with simvastatin 20 mg. The tolerability profiles of LIVALO and simvastatin were similar.

Extension Study

The extension study demonstrated a favorable safety and tolerability profile for LIVALO 4 mg over the 52-week trial. Reductions in LDL-C were sustained over the 52-week period. In addition, a higher proportion of LIVALO-treated patients met the defined LDL-C target at the end of the extension study than at the end of the core study (74.0% NCEP and 73.5% EAS). Steady increases in HDL-C were observed throughout the extension period, reaching more than 14%
'/>"/>

SOURCE Kowa Company Ltd., Kowa Pharmaceuticals America, Inc., and Kowa Research Institute, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
2. Noteworthy Medical Systems Demonstrates National Health Information Network (NHIN) Interoperability
3. Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation
4. Advanced Life Sciences Restanza Demonstrates Efficacy in Treating Anthrax Infection
5. Survey Demonstrates Marin County Residents Support Locally Owned and Operated Marin General Hospital
6. EVEREST Data Demonstrates Acute Reduction of Mitral Regurgitation Without Procedural Mortality in Patients Treated With the MitraClip(R) Therapy
7. VivaGel(R) Demonstrates Anti-HIV and Herpes Activity Following Human Administration
8. CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges
9. Study demonstrates the anti-inflammatory properties of pine bark extract
10. Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
11. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... This prestigious award is given ... made outstanding and innovative contributions to the physical ... private practice physical therapy by the Private Practice ... On behalf of Performance Physical Therapy, Michelle Collie ... Performance accepted the award at the Private Practice, ...
(Date:12/17/2014)... 17, 2014 In its comprehensive analysis ... its Argus Claim Review division have recently identified out-of-network ... common ways savings are achieved on behalf of employer-clients. ... of dollars in savings to Argus each year, with ... As explained by Tom Doney, Cypress president and CEO, ...
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Expectant parents should leave prenatal ... Administration recommends. Use of ultrasound imaging and heartbeat ... entirely risk-free, the agency warns. "Although there ... to ultrasound imaging and heartbeat monitors, prudent use of ... Shahram Vaezy, an FDA biomedical engineer, said in an ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, 2014 ... a new study reveals that states that routinely perform randomized ... on their roads. The finding suggests that states that ... deter inebriated revelers from getting behind the wheel in the ... regarding drinking and driving," said study lead author James Fell, ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3
... proven effective, tamoxifen could be new way to fight ... drug used to help prevent recurring breast cancer appears to ... research has found. , University of Rochester Medical Center researchers ... infections, which can be fatal to people with compromised ...
... NEW YORK, July 24 Empire BlueCross BlueShield and Stony ... reached agreement for a new contract, effective August 1, 2009. ... access to Stony Brook Hospital as in-network. , ... the long-standing relationship we have with Stony Brook," noted Mark ...
... WASHINGTON, July 24 Speaker Nancy Pelosi issued ... to fund the Departments of Labor, Health and Human Services, Education, ... federal funding for needle exchange, passed in the House by a ... "The fiscal year 2010 Labor-Health and Human Services-Education appropriations ...
... , , WEST ... Hollywood will never go away. Despite the poor economy, a ... the American Society of Plastic Surgeons. One would think the ... to take better care of their skin, but unfortunately summertime in ...
... , , , PORTLAND, ... has selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for ... user the past several years due to its proven success and effectiveness ... , Dr. Vu commented, "Artefill is a great product for ...
... , , , LANCASTER, ... 32 filed cases around the country have filed a joint motion asking ... Judge James G. Carr of the United States District Court for the ... 2009, before the Judicial Panel on Multidistrict Litigation in Washington, D.C. , ...
Cached Medicine News:Health News:Breast Cancer Drug May Beat Fungal Infection 2Health News:Pelosi Statement on House Passage of Labor, HHS, Appropriations Bill, Which Lifts Ban on Needle Exchange 2Health News:It Isn't Just Vanity! Local MedSpa Seeks to Correct and Educate. 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio 2
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Electrocardiogram (ECG) Devices - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... US$330 million by 2016. The North America ... global market share while Europe ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... April 27, 2012  Hill-Rom Holdings, Inc. (NYSE: HRC ... the Deutsche Bank Securities Health Care Conference in Boston on ... are invited to listen to the live discussion via the ... at http://www.media-server.com/m/p/2sfzaj9g . A recorded replay of the discussion ...
... Presented today by Tribeca Film Festival co-founder Craig ... Professor Clay Christensen and the Disruptor Foundation, Hanger ... CP, FAAOP and Area Practice Manager Dan Strzempka, ... Award.  Carroll and Strzempka received the award for ...
Cached Medicine Technology:Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award 2